Results 41 to 50 of about 5,463 (146)

Obinutuzumab activates FcγRI more potently than other anti-CD20 antibodies in chronic lymphocytic leukemia (CLL)

OncoImmunology, 2018
Treatment with monoclonal antibodies has revolutionized clinical medicine, especially in the fields of cancer and immunology. One of the oldest antibodies, which is widely used for the treatment of lymphomas and autoimmune diseases, is the anti-CD20 ...
Shlomo Elias, Shira Kahlon, Rebecca Kotzur, Noah Kaynan, Ofer Mandelboim   +4 more
doaj   +1 more source

Chemotherapy‐Sparing Strategies in Follicular Lymphoma: Emerging Targeted and Immune‐Based Approaches

European Journal of Haematology, Volume 116, Issue 4, Page 368-379, April 2026.
ABSTRACT Follicular lymphoma (FL), traditionally considered an indolent yet incurable malignancy, is experiencing a substantial evolution in its therapeutic landscape with the emergence of chemo‐free treatment strategies. These novel approaches challenge conventional chemotherapy‐based paradigms and offer promising alternatives for both newly diagnosed
Enrica Antonia Martino, Santino Caserta, Mamdouh Skafi, Maria Eugenia Alvaro, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Ernesto Vigna, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

Treatment resistant M-type phospholipase A2 receptor associated membranous nephropathy responds to obinutuzumab: a report of two cases

BMC Nephrology, 2022
Background Membranous Nephropathy (MN) is a common cause of nephrotic syndrome (NS) in adults. Recognition of MN as an antibody mediated autoimmune disease has enabled the introduction of anti-B-cell therapy.
Rebecca Hudson, Cassandra Rawlings, Saw Yu Mon, Julia Jefferis, George T. John   +4 more
doaj   +1 more source

Evaluation of the Efficacy and Safety of Satralizumab in a Pregnant NMOSD Patient With AQP4/MOG‐IgG Dual Seropositive: A Case Report

Annals of Clinical and Translational Neurology, Volume 13, Issue 3, Page 633-638, March 2026.
ABSTRACT Neuromyelitis Optica Spectrum Disorder (NMOSD) is a chronic autoimmune neuroinflammatory disease, typically characterized by antibodies against aquaporin 4 (AQP4‐IgG) or myelin oligodendrocyte glycoprotein (MOG‐IgG). Simultaneous seropositivity for both antibodies in a single patient is exceedingly rare.
Yeting Luo, Shuhua Xie, Xianghong Liu
wiley   +1 more source

Case‐Based Immunology: B Cells and Systemic Sclerosis Interstitial Lung Disease

Arthritis &Rheumatology, Volume 78, Issue 3, Page 566-581, March 2026.
Interstitial lung disease (ILD) is an important complication of systemic sclerosis (SSc), with high mortality and morbidity. Recent clinical studies in SSc‐ILD have led to US Food and Drug Administration–approved therapies in SSc‐ILD. Importantly, evidence from these studies has been extrapolated to guide management of ILDs of other systemic autoimmune
Nina Goldman, Voon Ong, Christopher P. Denton   +2 more
wiley   +1 more source

Obinutuzumab [PDF]

Reactions Weekly, 2020
  +5 more sources

Evaluation of Anticancer Therapy‐Related Tumor Flare Reaction: Insights From Food and Drug Administration's Adverse Event Reporting System Dataset

Cancer Medicine, Volume 15, Issue 3, March 2026.
ABSTRACT Aim Tumor flare reaction (TFR) is characterized by an increase in tumor size during immunotherapy, often resembling disease progression. This study explores the relationship between anti‐tumor drugs and tumor flare reaction (TFR) through the FAERS database to assist clinicians in better patient management.
Wei Wang, Jiayuan Cui, Yuxuan Bo, Yuxuan Wang, Zhipeng Sun, Xin Guan, Baoan Hong, Ning Zhang   +7 more
wiley   +1 more source

Disseminated Enteroviral Infection Associated with Obinutuzumab

Emerging Infectious Diseases, 2015
Two cases of disseminated enteroviral infection occurred in patients who received the CD20 monoclonal antibody obinutuzumab. Clinical features included hepatitis, edema, and a dermatomyositis-like syndrome.
Claire Dendle, Michael Gilbertson, Tony M. Korman, Vera Golder, Eric Morand, Stephen Opat   +5 more
doaj   +1 more source

Reduced‐Dose Bendamustine as a First‐Line Treatment of Follicular Lymphoma Is Associated With Poorer Prognosis

Cancer Medicine, Volume 15, Issue 3, March 2026.
ABSTRACT The dose of bendamustine used to treat previously untreated follicular lymphoma (FL) is sometimes reduced based on various clinical considerations, but the impact of such dose reductions on outcomes is unclear. We retrospectively analyzed 92 untreated FL patients treated with bendamustine at seven institutions in Japan.
Keisuke Tanaka, Atsushi Takahata, Yuma Noguchi, Keigo Okada, Tatsuya Saito, Junichi Mukae, Yuki Osada, Ken Suzuki, Daisuke Mizuchi, Koh Yamamoto, Takashi Kumagai, Gaku Oshikawa, Takehiko Mori, Shigeo Toyota, Masahide Yamamoto   +14 more
wiley   +1 more source

Successful management of belimumab after obinutuzumab in a patient with systemic lupus erythematosus: a case report with an 18-month follow-up

Frontiers in Immunology
IntroductionSystemic lupus erythematosus (SLE) is a complex autoimmune disease, and despite the availability of multiple treatments, striking a balance between long-term efficacy and side effects remains a major clinical challenge.
Xiuxiu Pu, Xiuxiu Pu, Qiao Ye, Lin Zhu, Lin Zhu, Tingting Yan   +5 more
doaj   +1 more source